ArticleCell2021
Spatially organized multicellular immune hubs in human colorectal cancer.
Open access · greenAbstract read
In one paragraph
Article in Cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 597 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
597citing papers in PubMed, 1 pooled it
37.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
597 citing papers in PubMed, 1 synthesis or guideline pooled it, 749 citations in OpenAlex.
- Cross-ancestry meta-analysis identifies a GSTP1 variant in the polycyclic aromatic hydrocarbons metabolism-related pathway contributing to colorectal cancer susceptibility.Archives of toxicology · 2026Pooled it
- Monocytes acquire a tumor-associated IL1B program upon encountering patient-derived colon cancer organoids.Oncoimmunology · 2026Article
- Stress-specific 14-3-3-client modules in digestive cancers: an evidence-graded review of adaptive survival and therapy resistance.Cancer biology & therapy · 2026Review
- An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.Oncoimmunology · 2026Article
- Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience · 2026Review
- Article
- Targeting myeloid cell plasticity and metabolic reprogramming to alleviate T cell dysfunction and exhaustion-associated states and enhance immune checkpoint blockade therapy.Biomarker research · 2026Review
- Tumor-Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy-Immunotherapy Combination Trials.International journal of cancer · 2026Review
- Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy.Nature immunology · 2026Article
- Canonical Wnt induction by OTULIN prevents keratinocyte death and skin inflammation.Science advances · 2026Article
- Integrated spatial and single-cell transcriptomics uncover IFI6⁺ regulatory T-cells and SPP1⁺ macrophages immunosuppressive niches in colorectal cancer.British journal of cancer · 2026Article
- Unveiling the role of spatial transcriptomics in the analysis of the tumor immune microenvironment (Review).International journal of molecular medicine · 2026Review
- Review
- Epithelial interferon-stimulated gene programs modulate chemotherapy sensitivity in colorectal cancer via EPSTI1.Oncogene · 2026Article
- An epithelial GPR35 isoform supports tumor-associated transcriptional and metabolic phenotypes.FEBS letters · 2026Article
- Spatial Transcriptomics and Mechanisms of Immune Checkpoint Inhibitor-Associated Interstitial Nephritis.Kidney international reports · 2026Article
- Liquid surrogates of spatial tumor ecosystems.Cell research · 2026Article
- Resolving cell-cell interaction networks and their molecular logic in complex tissues.Nature methods · 2026Article
- Temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window of opportunity for checkpoint inhibitor therapy in prostate cancer.Journal for immunotherapy of cancer · 2026Article
- RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.Science advances · 2026Article
537 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
72 authors at 9 institutions in 1 country.
Karin PelkaBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Massachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
Matan HofreeKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Jonathan H ChenBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Massachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA; Department of Pathology, MGH, Boston, MA, USA.
Siranush SarkizovaBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Joshua D PirlBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Vjola JorgjiMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA; Department of Pathology, MGH, Boston, MA, USA.
Alborz BejnoodKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Danielle DionneKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
William H GeBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Katherine H XuMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
Sherry X ChaoBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Department of Biomedical Informatics, HMS, Boston, MA, USA.
Daniel R ZollingerNanoString Technologies Inc., Seattle, WA, USA.
David J LiebBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Jason W ReevesNanoString Technologies Inc., Seattle, WA, USA.
Christopher A FuhrmanNanoString Technologies Inc., Seattle, WA, USA.
Margaret L HoangNanoString Technologies Inc., Seattle, WA, USA.
Toni DeloreyKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Lan T NguyenKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Julia WaldmanKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Max KlapholzEvergrande Center for Immunologic Diseases, HMS and Brigham and Women's Hospital (BWH), Boston, MA, USA.
Isaac WakiroCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA.
Ofir CohenBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Center for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA; Department of Medical Oncology, DFCI, Boston, MA, USA.
Julian AlbersBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Christopher S SmillieKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Michael S CuocoKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Jingyi WuCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA.
Mei-Ju SuCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA.
Jason YeungCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA.
Brinda VijaykumarDepartment of Immunology, HMS, Boston, MA, USA.
Angela M MagnusonDepartment of Immunology, HMS, Boston, MA, USA.
Natasha AsinovskiDepartment of Immunology, HMS, Boston, MA, USA.
Tabea MollClinical Research Center, MGH, Boston, MA, USA.
Max N Goder-ReiserClinical Research Center, MGH, Boston, MA, USA.
Anise S ApplebaumClinical Research Center, MGH, Boston, MA, USA.
Lauren K BraisClinical Research Center, DFCI, Boston, MA, USA.
Laura K DelloStrittoCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA.
Sarah L DenningClinical Research Center, DFCI, Boston, MA, USA.
Susannah T PhillipsClinical Research Center, MGH, Boston, MA, USA.
Emma K HillClinical Research Center, DFCI, Boston, MA, USA.
Julia K MeehanClinical Research Center, DFCI, Boston, MA, USA.
Dennie T FrederickClinical Research Center, MGH, Boston, MA, USA.
Tatyana SharovaClinical Research Center, MGH, Boston, MA, USA.
Abhay KanodiaCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA.
Ellen Z TodresBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Judit Jané-ValbuenaKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Moshe BitonKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Molecular Biology, MGH, Boston, MA, USA.
Benjamin IzarKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Center for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA; Department of Medical Oncology, DFCI, Boston, MA, USA.
Conner D LambdenEvergrande Center for Immunologic Diseases, HMS and Brigham and Women's Hospital (BWH), Boston, MA, USA.
Thomas E ClancyDepartment of Surgery, BWH, Boston, MA, USA.
Ronald BledayDepartment of Surgery, BWH, Boston, MA, USA.
Nelya MelnitchoukDepartment of Surgery, BWH, Boston, MA, USA.
Jennifer IraniDepartment of Surgery, BWH, Boston, MA, USA.
Hiroko KunitakeDepartment of Surgery, MGH, Boston, MA, USA.
David L BergerDepartment of Surgery, MGH, Boston, MA, USA.
Amitabh SrivastavaDepartment of Pathology, BWH, Boston, MA, USA.
Jason L HornickDepartment of Pathology, BWH, Boston, MA, USA.
Shuji OginoBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Department of Pathology, BWH, Boston, MA, USA.
Asaf RotemCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA.
Sébastien VigneauCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA.
Bruce E JohnsonCenter for Cancer Genomics, Department of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, MA, USA; Department of Medical Oncology, DFCI, Boston, MA, USA.
Ryan B CorcoranMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA; Department of Medicine, HMS, Boston, MA, USA.
Arlene H SharpeEvergrande Center for Immunologic Diseases, HMS and Brigham and Women's Hospital (BWH), Boston, MA, USA; Department of Immunology, Blavatnik Institute, HMS, Boston, MA, USA.
Vijay K KuchrooEvergrande Center for Immunologic Diseases, HMS and Brigham and Women's Hospital (BWH), Boston, MA, USA.
Kimmie NgDepartment of Medical Oncology, DFCI, Boston, MA, USA.
Marios GiannakisBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Department of Medical Oncology, DFCI, Boston, MA, USA.
Linda T NiemanMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
Genevieve M BolandMassachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA; Department of Surgery, MGH, Boston, MA, USA.
Andrew J AguirreBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Department of Medical Oncology, DFCI, Boston, MA, USA.
Ana C AndersonEvergrande Center for Immunologic Diseases, HMS and Brigham and Women's Hospital (BWH), Boston, MA, USA. Electronic address: acanderson@bwh.harvard.edu.
Orit Rozenblatt-RosenKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: orit@broadinstitute.org.
Aviv RegevKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Howard Hughes Medical Institute and Koch Institute for Integrative Cancer Research, Department of Biology, MIT, Cambridge, MA, USA. Electronic address: aviv.regev.sc@gmail.com.
Nir HacohenBroad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Massachusetts General Hospital (MGH) Cancer Center, Harvard Medical School (HMS), Boston, MA, USA; Department of Immunology, HMS, Boston, MA, USA. Electronic address: nhacohen@mgh.harvard.edu.
Broad Institute · USDana-Farber Cancer Institute · USMassachusetts Institute of Technology · USMen's Health Boston · USBrigham and Women's Hospital · USMGH Institute of Health Professions · USNanostring Technologies (United States) · USHarvard University · USMassachusetts General Hospital · US
Funding
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2MTraining Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8MThe Cellular Geography of Therapeutic Resistance in CancerU2CCA233195 · NCI · DANA-FARBER CANCER INST · PI JOHNSON, BRUCE E. · 2018 to 2023
$13.7MProject 2: Genes required for dendritic cell responses to pathogens and T cellsU19AI133524 · NIAID · HARVARD MEDICAL SCHOOL · PI SHARPE, ARLENE H. · 2017 to 2021
$12.3MSystems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI SORGER, PETER KARL · 2018 to 2022
$10.8MProject 2U54CA224068 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CORCORAN, RYAN BRUCE, FLAHERTY, KEITH T · 2017 to 2021
$6.3MAccelerating Transdisciplinary Epidemiology of Colorectal CancerR35CA197735 · NCI · DANA-FARBER CANCER INST · PI OGINO, SHUJI · 2015 to 2021
$6.0MNovel randomized controlled trials of vitamin D supplementation in patients with colorectal cancer: Impact on survival and biologyR01CA205406 · NCI · DANA-FARBER CANCER INST · PI Kimmie Ng · 2017 to 2026
$4.9MSystematic interrogation of the pancreatic cancer microenvironment in patient-derived specimensU01CA224146 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2017 to 2021
$3.0M(PQ3) The role of damaged DNA in inter-individual variation of tumor immunityR01CA208756 · NCI · BROAD INSTITUTE, INC. · PI HACOHEN, NIR · 2016 to 2020
$2.6MCancer Immunology Training GrantT32CA207021 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2016 to 2020
$2.4MThe Immune Cell Atlas â A Robust Framework to Map the Entire Human Immune SystemR56AI137244 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BENOIST, CHRISTOPHE O., HACOHEN, NIR · 2018 to 2018
$2.0MNCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCI NIH HHS K08 CA218420NCI NIH HHS K08 CA222663NCI NIH HHS K99 CA259511NCI NIH HHS P50 CA127003NCI NIH HHS R00 CA259511NCI NIH HHS R01 CA205406NCI NIH HHS R01 CA208756NCI NIH HHS R33 CA160344NCI NIH HHS R35 CA197735NCI NIH HHS T32 CA207021NCI NIH HHS U01 CA224146NCI NIH HHS U2C CA233195NCI NIH HHS U54 CA224068NCI NIH HHS U54 CA225088NHGRI NIH HHS T32 HG002295NIAID NIH HHS R56 AI137244NIAID NIH HHS U19 AI133524
Abstract
Immune responses to cancer are highly variable, with mismatch repair-deficient (MMRd) tumors exhibiting more anti-tumor immunity than mismatch repair-proficient (MMRp) tumors. To understand the rules governing these varied responses, we transcriptionally profiled 371,223 cells from colorectal tumors and adjacent normal tissues of 28 MMRp and 34 MMRd individuals. Analysis of 88 cell subsets and their 204 associated gene expression programs revealed extensive transcriptional and spatial remodeling across tumors. To discover hubs of interacting malignant and immune cells, we identified expression programs in different cell types that co-varied across tumors from affected individuals and used spatial profiling to localize coordinated programs. We discovered a myeloid cell-attracting hub at the tumor-luminal interface associated with tissue damage and an MMRd-enriched immune hub within the tumor, with activated T cells together with malignant and myeloid cells expressing T cell-attracting chemokines. By identifying interacting cellular programs, we reveal the logic underlying spatially organized immune-malignant cell networks.
Indexed as
Bone Morphogenetic ProteinsCancer-Associated FibroblastsCell CompartmentationCell Line, TumorChemokinesCohort StudiesColorectal NeoplasmsDNA Mismatch RepairEndothelial CellsGene Expression Regulation, NeoplasticHumansImmunityInflammationMonocytesMyeloid CellsNeutrophilsBone Morphogenetic ProteinsChemokinesanti-tumor immunitycell-cell interactionscolorectal cancermismatch repair-deficientmismatch repair-proficientMSIMSSscRNA-seqspatialtumor atlas
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.